Tylenol autism – Health Secretary Robert F. Kennedy Jr. rejected new Danish research finding no Tylenol-autism link, calling it fraudulent and urging retraction—while experts say the study addresses key bias concerns.
Health Secretary Robert F. Kennedy Jr. is pushing back hard against a new study finding no link between Tylenol use during pregnancy and autism.
During a Friday hearing before the House Committee on Education and Workforce, Kennedy called the Danish research “garbage” and said it “should be retracted,” escalating a political fight that has quickly become a flashpoint for public trust in medical evidence.
The study. published in JAMA Pediatrics this week. analyzed medical records from more than a million women in Denmark to evaluate whether acetaminophen use—commonly sold as Tylenol—was associated with autism in children.. Kennedy argued that because the research relied on prescription data. it only captured a slice of patients who took acetaminophen in ways that appeared in official records. potentially skewing results.
His criticism centered on a familiar concern in health research: if certain exposures aren’t fully measured. the conclusion can be misleading.. Kennedy described the study as “garbage in. garbage out. ” suggesting that pharmaceutical and research pathways can produce results that reflect how data are collected rather than how risks truly play out.
Yet the published paper addressed this exact issue.. It stated that the “true exposure level” among women with lower levels of acetaminophen exposure may have been underestimated. but it also noted that in prior work examining over-the-counter drugs. such bias has tended to be “largely negligible.” Another study from 2021 similarly found that non-recorded use of drugs like aspirin and NSAIDs had a “virtually negligible” effect on determining true usage—an important point because it goes directly to Kennedy’s methodological objections.
In the hearing. Kennedy’s challenge also appeared tied to a broader narrative he has promoted about an “autism epidemic” and its causes.. Nearly a year ago. he said he would identify the cause by September; when that deadline passed. he indicated his office was working to show that taking Tylenol during pregnancy can cause autism. even while acknowledging that conclusive evidence has not emerged.
That tension has real-world consequences.. Pregnant people often face difficult choices in real time—balancing comfort. fever management. and guidance from clinicians—while conflicting messages from public figures can amplify anxiety.. When officials question mainstream findings. the effect can ripple beyond one study. influencing how families interpret medical advice and what they fear.
The debate has also been fueled by prior international research. A separate study out of Sweden in 2024 similarly reported no causal link between acetaminophen and autism among siblings, adding another data point to a growing body of work that does not support Kennedy’s framing.
Still, supporters of caution argue that uncertainty should not be dismissed simply because a study finds no association.. Misuse of medicines during pregnancy can be harmful, and the public deserves careful communication.. The question is whether the response should be retraction of a peer-reviewed paper—or tighter. more transparent discussion of what evidence can and cannot currently prove.
Misryoum notes that this moment reflects a larger political pattern: scientific disputes increasingly play out in committee rooms. not just journals.. When high-profile officials label studies as fraudulent without accepting their limitations and bias assessments. it shifts the burden of proof from “what the data show” to “whether the messenger can be trusted.” For families trying to make decisions. that can blur the line between legitimate scientific debate and ideological conflict.
One biostatistics expert, Dr.. Jeffrey S.. Morris. criticized Kennedy’s approach in an online response. saying the criticism overlooks how the paper handled the bias issue Kennedy raised.. Morris argued that the study also found no elevated autism risk among children of high-dose prescription users—an outcome that. under Kennedy’s framework. would have been expected to show greater harm if the risk were real.
At the center of this dispute is a fundamental responsibility: acknowledging uncertainty without turning every non-supportive result into a reason to reject the method itself.. The Danish study did not claim acetaminophen is risk-free in all circumstances; it focused on whether there is an observed link to autism outcomes based on its dataset.. In public health, that kind of distinction matters—because decisions depend on whether evidence supports association, causation, or neither.
Moving forward, Misryoum expects the political pressure around acetaminophen and autism to keep intensifying, especially as additional analyses continue to test exposure measurement, prescription versus over-the-counter use, and whether sibling or registry comparisons change the results.
But the key immediate takeaway for pregnant people and clinicians is narrower: the newest evidence reported no link in a large dataset. and the paper explicitly addressed the concern Kennedy raised about low-level exposure measurement.. Whether that is enough for policymakers to change course—or for critics to accept the limits of what any study can measure—may determine whether this debate settles into careful follow-up or continues to become a public referendum on medical research itself.
Kenvue. the maker of Tylenol. did not immediately respond to a request for comment. and Kennedy’s office did not respond to questions about the earlier methodological study.. For now. Misryoum will keep tracking how this controversy shapes guidance. hearings. and the trust relationship between science. policy. and the families trying to protect their children.
White House Meets Anthropic CEO on Mythos AI Model
Tornado Damage in Lena, Illinois: Town Shut Down
Trump hints at sinister pattern in lab deaths—Misryoum says no link